Who Optimizes SG&A Costs Better? Incyte Corporation or ImmunityBio, Inc.

Optimizing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Incyte Corporation and ImmunityBio, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Incyte consistently reported higher SG&A expenses, peaking at $1.16 billion in 2023, a 600% increase from 2014. In contrast, ImmunityBio's expenses grew more modestly, with a 2900% increase, reaching $129 million in 2023. This disparity highlights Incyte's aggressive investment in administrative functions, possibly reflecting a strategy to support rapid growth. Meanwhile, ImmunityBio's more conservative approach may indicate a focus on lean operations. As these companies continue to evolve, their SG&A strategies will be pivotal in shaping their competitive edge in the biotech industry.